AXSMAxsome Therapeutics, Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Rangebound, no clear trend. Oversold (RSI 6). Price is −13% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, about a week of normal trading to cover. Up 1.9% since the previous count, down from 6.4% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How AXSM is trading
Axsome Therapeutics, Inc. is +45% over the past year while the S&P 500 is +18%: 27 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −13%
vs 200-day average · a clear downtrend
- RSI (14)
- 6
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 34%
Below its 52-week high
Details›
- Last close2026-10-09
- $168.44
- 1 monthS&P 500 +2.7%
- −20%
- 1 yearS&P 500 +18%
- +45%
- 5 yearsS&P 500 +88%
- +544%
- vs 50-day average$204.13
- −17%
- 52-week high
- $255.17
- 52-week low
- $116.01
- Annualised volatility
- 45%
| Year | Return |
|---|---|
| 2026 (year to date) | −7.8% |
| 2025 | +116% |
| 2024 | +6.3% |
| 2023 | +3.2% |
| 2022 | +104% |
| 2021 | −54% |
| 2020 | −21% |
| 2019 | +3565% |
| 2018 | −50% |
| 2017 | −17% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +9.7% |
| Feb | 10 | 2 of 10 | −4.0% |
| Mar | 10 | 3 of 10 | +5.0% |
| Apr | 10 | 7 of 10 | +14% |
| May | 10 | 4 of 10 | −0.87% |
| Jun | 10 | 7 of 10 | +13% |
| Jul | 11 | 5 of 11 | −2.8% |
| Aug | 11 | 6 of 11 | +3.4% |
| Sep | 11 | 5 of 11 | −2.4% |
| Oct | 11 | 5 of 11 | +0.32% |
| Nov | 10 | 7 of 10 | +15% |
| Dec | 10 | 7 of 10 | +20% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.